Cholera toxin - A foe & a friend

Indian Journal of Medical Research

Volumn 133, Issue 2, 2011, Pages 153-163

  Sánchez, Joaquín ^a   Holmgren, Jan ^b  

^a Facultad de Medicina UASLP   (Mexico)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Allergy; Autoimmune disease; Cholera toxin phage; Cholera vaccine; GM1 ganglioside; Immunological tolerance; Intracellular toxin traffic; Receptor binding site; Toxin secretion; Virulence gene regulation

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; CYCLIC AMP; GANGLIOSIDE GM1; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE RECEPTOR; PROTEIN SUBUNIT;

BACTERIOPHAGE; GENE EXPRESSION; GENETIC ORGANIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INTESTINE SECRETION; INTRACELLULAR TRANSPORT; REVIEW; VIBRIO CHOLERAE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUCOSAL IMMUNITY; PATHOGENICITY; PROTEIN CONFORMATION;

CHOLERA TOXIN; CHOLERA VACCINES; HUMANS; IMMUNITY, MUCOSAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN SUBUNITS; VIBRIO CHOLERAE;

EID: 79953005700     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. De SN. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 1959; 183: 1533-1534.
2. Finkelstein RA, LoSpalluto JJ. Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid. J Exp Med 1969; 130: 185-202.
3. Lonnroth I, Holmgren J. Subunit structure of cholera toxin. J Gen Microbiol 1973; 76: 417-427.
4. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 1981; 292: 413-417.
5. Holmgren J, Lonnroth I, Svennerholm L. Tissue receptor for cholera exotoxin postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun 1973; 8: 208-214.
6. Sixma TK, Kalk KH, van Zanten BA, Dauter Z, Kingma J, Witholt B, et al. Refined structure of Escherichia coli heat- labile enterotoxin, a close relative of cholera toxin. J Mol Biol 1993; 230: 890-918.
7. Merritt EA, Sarfaty S, Chang TT, Palmer LM, Jobling MG, Holmes RK, et al. Surprising leads for a cholera toxin receptor-binding antagonist crystallographic studies of CTB mutants. Structure 1995; 3: 561-570.
8. Tamplin ML, Aimed MK, Jalali R, Colwell RR. Variation in epitopes of the B subunit of El Tor and classical biotype Vibrio cholerae 01 cholera toxin. J Gen Microbiology 1989; 135: 1195-1200.
9. Olsvik O, Wahlberg J, Petterson B, Uhlen M, Popovic T, Wachsmuth IK, et al. Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains. J Clin Microbiol 1993; 31: 22-25.
10. Nair GB, Qadri F, Holmgren J, Svennerholm AM, Safa A, Bhuiyan NA, et al. Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh J Clin Microbiol 2006; 44: 4211-4213.
11. Safa A, Nair GB, Kong RY. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 2010; 18: 46-54.
12. Dubey RS, Lindblad M, Holmgren J. Purification of El Tor cholera enterotoxins and comparisons with classical toxin. J Gen Microbiol 1990; 136: 1839-1847.
13. Pearson GD, Mekalanos JJ. Molecular cloning of Vibrio cholerae enterotoxin genes in Escherichia coli K-12. Proc Natl Acad Sci USA 1982; 79: 2976-2980.
14. Davis BM, Waldor MK. Filamentous phages linked to virulence of Vibrio cholerae. Curr Opin Microbiol 2003; 6: 35-42.
15. Bhattacharya T, Chatterjee S, Maiti D, Bhadra RK, Takeda Y, Nair GB, et al. Molecular analysis of the rstR and orfU genes of the CTX prophages integrated in the small chromosomes of environmental Vibrio cholerae non-O1 non-O139 strains. Environ Microbiol 2006; 8: 526-634.
16. Campos J, Martínez E, Marrero K, Silva Y, Rodríguez BL, Suzarte E, et al. Novel type of specialized transduction for CTXΦ or its satellite phage RS1 mediated by filamentous phage VGJΦ in Vibrio cholerae. J Bacteriol 2003; 185: 7231-7240.
17. Yu RR, DiRita VJ. Analysis of an autoregulatory loop controlling ToxT, cholera, toxin, and toxin-coregulated pilus production in Vibrio cholerae. J Bacteriol 1999; 181: 2584- 2592.
18. Beck NA, Krukonis ES, DiRita VJ. TcpH influences virulence gene expression in Vibrio cholerae by inhibiting degradation of the transcription activator TcpP. J Bacteriol 2004; 186: 8309-8316.
19. Lin W, Kovacikova G, Skorupski K. The quorum sensing regulator HapR downregulates the expression of the virulence gene transcription factor AphA in Vibrio cholerae by antagonizing Lrp- and VpsR-mediated activation. Mol Microbiol 2007; 64: 953-967.
20. Childers BM, Klose KE. Regulation of virulence in Vibrio cholerae: the ToxR regulon. Future Microbiol 2007; 2: 335-344.
21. Osorio CG, Crawford JA, Michalski J, Martinez-Wilson H, Kaper JB, Camilli A. Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine. Infect Immun 2005; 73: 972-980.
22. Medrano AI, DiRita VJ, Castillo G, Sanchez J. Transient transcriptional activation of the Vibrio cholerae El Tor virulence regulator toxT in response to culture conditions. Infect Immun 1999; 67: 2178-2183.
23. Bina J, Zhu J, Dziejman M, Faruque S, Calderwood S, Mekalanos JJ. ToxR regulon of Vibrio cholerae and its expression in vibrios shed by cholera patients. Proc Natl Acad Sci USA 2003; 100: 2801-2806.
24. Sanchez J, Castillo G, Medrano AI, Martínez-Palomo A, Rodriguez MH. In vitro growth of Vibrio cholerae in cholera stool fluid leads to differential expression of virulence factors. Arch Med Res 1995; 26 (Suppl 5): S47-S53.
25. Johnson TL, Abendroth J, Hol WG, Sandkvist M. Type II secretion: from structure to function. FEMS Microbiol Lett 2006; 255: 175-186.
26. Davis BM, Lawson EH, Sandkvist M, Ali A, Sozhamannan S, Waldor MK. Convergence of the secretory pathways for cholera toxin and the filamentous phage CTXΦ. Science 2000; 288: 333-335.
27. Hirst TR, Sanchez J, Kaper JB, Hardy SJ, Holmgren J. Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc Natl Acad Sci USA 1984; 81: 7752-7756.
28. Hardy SJ, Holmgren J, Johansson S, Sanchez J, Hirst TR. Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc Natl Acad Sci USA 1988; 85: 7109-7113.
29. Sanchez J, Hirst TR, Uhlin BE. Hybrid enterotoxin LTA: STa proteins and their protection from degradation by in vivo association with B-subunits of Escherichia coli heat-labile enterotoxin. Gene 1988; 64: 265-275.
30. Majoul I, Schmidt T, Pomasanova M, Boutkevich E, Kozlov Y, Söling HD. Differential expression of receptors for shiga and cholera toxin is regulated by the cell cycle. J Cell Sci 2002; 115: 817-826.
31. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci 1994; 3: 166-175.
32. Merritt EA, Sarfaty S, Chang TT, Palmer LM, Jobling MG, Holmes RK, et al. Surprising leads for a cholera toxin receptor- binding antagonist: crystallographic studies of CTB mutants. Structure 1995; 3: 561-570.
33. Feng Y, Jadhav AP, Rodighiero C, Fujinaga Y, Kirchhausen T, Lencer WI. Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2- treated cells. EMBO Rep 2004; 5: 596-601.
34. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, et al. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell 2003; 14: 4783-4793.
35. Wernick NLB, Chinnapen D J-F, Cho JA, Lencer WI. Cholera toxin: An intracellular journey into the cytosol by way of the endoplasmic reticulum. Toxins 2010; 2: 310-325.
36. Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum- associated protein degradation pathway to enter target cells. Biochemistry 1997; 36: 11051-11054.
37. Tsai B, Rapoport TA. Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. J Cell Biol 2002; 159: 207-216.
38. O'Neal CJ, Jobling MG, Holmes RK, Hol WG. Structural basis for the activation of cholera toxin by human ARF6-GTP. Science 2005; 309: 1093-1096.
39. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS. Lectin conjugates as potent non-absorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 2007; 132: 1234-1244.
40. Lundgren O. Enteric nerves and diarrhoea. Pharmacol Toxicol 2002; 90: 109-120.
41. Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 97: 181-188.
42. Holmgren J, Bergquist, C. Oral B-subunit-killed whole-cell cholera vaccine. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, editors. New generation vaccines. New York: Marcel Dekker; 2009. p. 991-914.
43. th ed. New York: Marcel Dekker; 2009. p. 499-509.
44. Svennerholm AM, Tobias J. Vaccines against enterotoxigenic Eschericha coli. Expert Rev Vaccines 2008; 7: 795-804.
45. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11 (Suppl 4): S45-S53.
46. George-Chandy A, Eriksson K, Lebens M, Nordstrom I, Schon E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun 2001; 69: 5716-5725.
47. Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 1991; 146: 2908-2914.
48. Sanchez J, Wallerström G, Fredriksson M, Ångstrom J, Holmgren, J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J Biol Chem 2002; 277: 33369-33377.
49. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23: 1804-1813.
50. Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 2005; 5: 591-597.
51. Adamsson J, Lindblad M, Lundqvist A, Kelly D, Holmgren J, Harandi AM. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 2006; 176: 4902-4913.
52. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91: 10795-10799.
53. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2010; 71: 1-11.
54. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137: 201-208.